Ferring Pharmaceuticals said last week that the FDA approved its injectable somatropin product for four additional pediatric indications: idiopathic short stature, short stature associated with Turner syndrome, short stature born small for gestational age with no catch-up growth by 2 – 4 years and growth failure in short stature homeobox-containing gene deficiency.
In connection with the new approvals, Ferring plans to launch a needle-free drug-delivery system for its somatropin product in September this year.
Get the full story at our sister site, Drug Delivery Business News.